NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/08/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,200.48 mln
Float144 mln
Earnings Date07/30/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
35.64
Transformational upside
Relative Strength
25
/ 100
Underperforming
Debt / Equity
0.04
Debt-free
ROE
-48.18
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Denali Therapeutics is a biopharmaceutical company based in South San Francisco, California, focused on developing treatments for brain-related and rare metabolic diseases, including Parkinson's disease, Alzheimer's disease, frontotemporal dementia, and several lysosomal storage disorders. The company has built a broad pipeline of drug candidates that work through a variety of approaches, including enzyme replacement, gene therapy, and small molecule inhibitors. Originally founded in 2013 under the name SPR Pharma, Denali has grown into a clinical-stage company with multiple programs advancing through development, several of which are being pursued in partnership with large pharmaceutical companies.
